Selagibenzophenone B and Its Derivatives:
Journal
ACS bio & med chem Au
ISSN: 2694-2437
Titre abrégé: ACS Bio Med Chem Au
Pays: United States
ID NLM: 9918232604406676
Informations de publication
Date de publication:
21 Aug 2024
21 Aug 2024
Historique:
received:
24
04
2024
revised:
26
06
2024
accepted:
27
06
2024
medline:
26
8
2024
pubmed:
26
8
2024
entrez:
26
8
2024
Statut:
epublish
Résumé
The development of multitargeted drugs represents an innovative approach to cancer treatment, aiming to enhance drug effectiveness while minimizing side effects. Herein, we sought to elucidate the inhibitory effect of selagibenzophenone B derivatives on the survival of cancer cells and dual topoisomerase I/II enzyme activity. Results demonstrated that among the compounds,
Identifiants
pubmed: 39184056
doi: 10.1021/acsbiomedchemau.4c00027
pmc: PMC11342340
doi:
Types de publication
Journal Article
Langues
eng
Pagination
178-189Informations de copyright
© 2024 The Authors. Published by American Chemical Society.
Déclaration de conflit d'intérêts
The authors declare no competing financial interest.